Quick Takeaways
- AbbVie Biotechnology Ltd filed SCHEDULE 13G/A for Carisma Therapeutics Inc. Common Stock, $0.001 par value (CARM).
- Disclosed ownership: 4.4%.
- Date of event: 31 Mar 2025.
AbbVie Biotechnology Ltd - 31 Mar 2025 SCHEDULE 13G/A Report for Carisma Therapeutics Inc. Common Stock, $0.001 par value (CARM)
- Filing Manager
- AbbVie Biotechnology Ltd
- Reporting Manager
- AbbVie Biotechnology Ltd.
- Symbol
- CARM
- Shares outstanding
- 42,178,886 shares
- Disclosed Ownership
- 1,855,871 shares
- Ownership
- 4.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 25 Apr 2025, 16:15:16 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"AbbVie Biotechnology Ltd disclosed 4.4% ownership in Carisma Therapeutics Inc. Common Stock, $0.001 par value (CARM) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 25 Apr 2025, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| AbbVie Biotechnology Ltd. | 4.4% | 1,855,871 | 0 | 1,855,871 | /s/ Arthur C. Price | Arthur C. Price/Director |